SG11202100385YA - Use of riluzole prodrugs to treat alzheimer's disease - Google Patents
Use of riluzole prodrugs to treat alzheimer's diseaseInfo
- Publication number
- SG11202100385YA SG11202100385YA SG11202100385YA SG11202100385YA SG11202100385YA SG 11202100385Y A SG11202100385Y A SG 11202100385YA SG 11202100385Y A SG11202100385Y A SG 11202100385YA SG 11202100385Y A SG11202100385Y A SG 11202100385YA SG 11202100385Y A SG11202100385Y A SG 11202100385YA
- Authority
- SG
- Singapore
- Prior art keywords
- patient
- administered
- riluzole
- disease
- riluzole prodrug
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862701814P | 2018-07-22 | 2018-07-22 | |
| PCT/US2019/042718 WO2020023324A1 (en) | 2018-07-22 | 2019-07-20 | Use of riluzole prodrugs to treat alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202100385YA true SG11202100385YA (en) | 2021-02-25 |
Family
ID=69181140
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202100385YA SG11202100385YA (en) | 2018-07-22 | 2019-07-20 | Use of riluzole prodrugs to treat alzheimer's disease |
Country Status (14)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL299301A (en) * | 2020-06-24 | 2023-02-01 | Biohaven Therapeutics Ltd | Compositions and methods for the treatment of obsessive compulsive disorder |
| EP4240308A4 (en) * | 2020-10-05 | 2024-10-30 | Icahn School of Medicine at Mount Sinai | Riluzole for the treatment of alzheimer's disease |
| WO2022155564A1 (en) * | 2021-01-18 | 2022-07-21 | Biohaven Therapeutics Ltd. | Use of riluzole prodrugs to treat alzheimer's disease |
| BR112023016690A2 (pt) * | 2021-02-22 | 2023-11-14 | Univ Yale | Degradadores bifuncionais direcionados e métodos usando os mesmos |
| CN114344297B (zh) * | 2022-03-01 | 2024-05-14 | 暨南大学 | 利鲁唑在治疗少精症中的应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001275525B2 (en) * | 2000-06-14 | 2007-04-26 | Medarex, Inc. | Tripeptide prodrug compounds |
| EP1814558B1 (en) * | 2004-11-01 | 2010-12-15 | Seo Hong Yoo | Methods and compositions for reducing neurodegeneration in amyotrophic lateral sclerosis |
| FR2957077B1 (fr) * | 2010-03-02 | 2012-04-13 | Univ Dauvergne Clermont I | Utilisation du riluzole pour traiter ou prevenir les effets indesirables d'agents anti-cancereux |
| WO2015089049A1 (en) | 2013-12-09 | 2015-06-18 | Thomas Jefferson University | Novel methods of treating a neurodegenerative disease in a mammal in need thereof |
| US10258611B2 (en) * | 2014-11-26 | 2019-04-16 | Medicinova, Inc. | Combination of ibudilast and riluzole and methods of using same |
| DK3265448T3 (da) * | 2015-03-03 | 2022-03-28 | Biohaven Therapeutics Ltd | Riluzol-prodrugs og anvendelse deraf |
| HRP20220237T1 (hr) * | 2016-05-20 | 2022-04-29 | Biohaven Therapeutics Ltd. | Primjena riluzola, prolijekova riluzola ili analoga riluzola sa imunoterapijama za liječenje raka |
| US12029731B2 (en) * | 2016-08-10 | 2024-07-09 | Biohaven Therapeutics Ltd. | Acyl benzo[d]thiazol-2-amine and their methods of use |
| US10751345B2 (en) * | 2018-02-21 | 2020-08-25 | AI Therapeutics, Inc. | Combination therapy with apilimod and glutamatergic agents |
| WO2022155564A1 (en) * | 2021-01-18 | 2022-07-21 | Biohaven Therapeutics Ltd. | Use of riluzole prodrugs to treat alzheimer's disease |
-
2019
- 2019-07-20 JP JP2021503571A patent/JP2021530543A/ja active Pending
- 2019-07-20 US US17/261,057 patent/US12161633B2/en active Active
- 2019-07-20 KR KR1020217004639A patent/KR20210034621A/ko not_active Ceased
- 2019-07-20 AU AU2019310013A patent/AU2019310013B2/en active Active
- 2019-07-20 WO PCT/US2019/042718 patent/WO2020023324A1/en not_active Ceased
- 2019-07-20 CA CA3107215A patent/CA3107215A1/en active Pending
- 2019-07-20 BR BR112021000768-7A patent/BR112021000768A2/pt unknown
- 2019-07-20 EP EP19841953.3A patent/EP3823616A4/en active Pending
- 2019-07-20 IL IL280177A patent/IL280177B2/en unknown
- 2019-07-20 CN CN201980048687.7A patent/CN112469408A/zh active Pending
- 2019-07-20 EA EA202190308A patent/EA202190308A1/ru unknown
- 2019-07-20 MX MX2021000515A patent/MX2021000515A/es unknown
- 2019-07-20 SG SG11202100385YA patent/SG11202100385YA/en unknown
-
2021
- 2021-01-07 PH PH12021550043A patent/PH12021550043A1/en unknown
- 2021-01-14 MX MX2024010655A patent/MX2024010655A/es unknown
-
2025
- 2025-02-21 JP JP2025026643A patent/JP2025093952A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019310013B2 (en) | 2025-01-02 |
| WO2020023324A1 (en) | 2020-01-30 |
| MX2021000515A (es) | 2021-06-08 |
| IL280177A (en) | 2021-03-01 |
| IL280177B1 (en) | 2024-09-01 |
| CA3107215A1 (en) | 2020-01-30 |
| JP2021530543A (ja) | 2021-11-11 |
| EP3823616A1 (en) | 2021-05-26 |
| EP3823616A4 (en) | 2022-05-04 |
| NZ772009A (en) | 2026-02-27 |
| BR112021000768A2 (pt) | 2021-05-11 |
| AU2019310013A1 (en) | 2021-02-11 |
| PH12021550043A1 (en) | 2021-09-20 |
| KR20210034621A (ko) | 2021-03-30 |
| US12161633B2 (en) | 2024-12-10 |
| CN112469408A (zh) | 2021-03-09 |
| MX2024010655A (es) | 2024-09-11 |
| IL280177B2 (en) | 2025-01-01 |
| EA202190308A1 (ru) | 2021-05-19 |
| US20210290599A1 (en) | 2021-09-23 |
| JP2025093952A (ja) | 2025-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL280177A (en) | Use of riluzole prodrugs to treat Alzheimer's disease | |
| IL276493A (en) | Carbidopa and L-dopa prodrugs and methods for use in the treatment of Parkinson's disease | |
| IL271046A (en) | Compounds for treating huntington's disease | |
| IL265528A (en) | aav therapy for Huntington's disease | |
| IL274648A (en) | Promote new catecholamine drugs for use in the treatment of Parkinson's disease | |
| IL254030B (en) | Use of pyridofidine to improve cognitive function and to treat Alzheimer's disease | |
| EP3562514A4 (en) | GENE THERAPY FOR THE TREATMENT OF WILSON'S DISEASE | |
| IL275321A (en) | Treatment of diseases associated with the expression of DUX4 | |
| IL274532A (en) | Using the prodrug riluzole to treat ataxias | |
| LT3463351T (lt) | Parkinsono ligos gydymas | |
| SG11202011187QA (en) | Use of riluzole oral disintigrating tablets for treating diseases | |
| IL280657A (en) | Use of riluzole oral dissolving tablets to treat diseases | |
| EP4277624A4 (en) | USE OF RILUZOLE PRODRUGS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | |
| IL290726A (en) | Use of Brazicomb to treat Crohn's disease | |
| PL3352742T3 (pl) | Kompozycje zawierające triterpenoidy do leczenia choroby alzheimera i choroby parkinsona | |
| HK40041745A (en) | Use of riluzole prodrugs to treat alzheimer's disease | |
| ES3065944T3 (en) | Use of riluzole prodrugs to treat ataxias | |
| HK40068889A (en) | Use of brazikumab to treat crohn's disease | |
| HK40037165A (en) | Catecholamine prodrugs for use in the treatment of parkinson's disease | |
| AU2017902307A0 (en) | Treatment of alzheimer's disease | |
| AU2017902309A0 (en) | Treatment of alzheimer's disease | |
| GB201511453D0 (en) | Treatment of alzheimer's disease | |
| GB201504144D0 (en) | Treatment of Parkinson's disease |